The outcomes behind Nervana
Progress you can see,
from symptoms to everyday life
01 / Symptom relief
For members who started with high symptom severity
29%*1
85% reported an improvement
Average symptom severity · 0–10 scale
*1 40 matched respondents with starting severity 7–10. Average change from baseline to a check-in within 14 days after session 10.
02 / Healthcare use
Less symptom-related urgent care in the first follow-up
50%*2
At the 30-day follow-up
Estimated visits per person per month
*2 67 matched respondents. Self-reported visit ranges converted to monthly estimates, comparing the prior 90 days with the follow-up’s prior 30 days.
03 / Out-of-pocket costs
Early spending results from members with longer follow-up
48%*3
At the 90-day follow-up
Estimated out-of-pocket dollars per month
*3 17 matched respondents. Estimated monthly spending from self-reported ranges. Spending did not decrease at the 30-day follow-up.
04 / Member experience
91%*4
*4 96 of 105 respondents rated Nervana helpful or reported a specific benefit in their session-10 check-in.
From outcomes to research
Sharing what we learn as the evidence grows
PAINWeek 2026 · Research poster
Early real-world symptom trends and perceived helpfulness among people using Nervana.
Read the full posterObservational research with self-reported outcomes and no control group. The poster reports its original study cohort.
These studies informed Nervana’s approach. They tested clinician-delivered therapies, rather than the Nervana app.
Ashar et al. · 2022 · Randomized trial · 151 adults with primary chronic back pain
Donnino et al. · 2021 · Randomized pilot · 35 adults included in the analysis
Yarns et al. · 2024 · Randomized trial · 126 older veterans with musculoskeletal pain
How Nervana AI is built
Research, personal context, and human clinical guidance shape each conversation.
A knowledge base of research, lessons, and coaching guidance
Your experiences, reflections, and preferences
Clinical guidance reviewed by our medical advisors
Meet our advisors Personalized, action-oriented support
Designed around medical and emotional safetyPersonal memory helps the coach build on your story. Knowledge-base improvements go through human review before they are approved. How we handle your information
Outcome data updated October 29, 2026
Internal, self-reported, observational data from respondents with matched measurements. Results do not establish cause and effect or guarantee individual outcomes. Nervana complements medical care.
Test and analytics-excluded accounts, plus active partner-access accounts other than guest passes, are excluded. Each outcome has its own respondent group; missing and declined answers are excluded from that outcome.
*1 Symptom severity: The first submitted 0–10 severity score is the baseline. High severity means 7–10. We use the first submitted check-in on or after completed session 10 and within 14 days. Every included completion had a full 14-day observation window. 40 of 52 eligible high-severity members had matched follow-up data; 34 reported a lower score. The 29% result is the change in the group’s average severity, rather than the percentage of members who improved. Session 10 is an app milestone, not a fixed number of days.
*2 Care use: 67 members answered both baseline and 30-day follow-up visit questions. Baseline covers the prior 90 days and is divided by three; follow-up covers the prior 30 days. Visit ranges use representative values, with “4 or more” set to 4. The percentage uses unrounded group averages; chart labels are rounded. These are symptom-related urgent care and ER visits, rather than all healthcare use.
*3 Spending: 17 members answered both baseline and 90-day follow-up spending questions. Dollar ranges use representative values and the same monthly conversion. Top ranges are capped at their lower bound. These are estimates, rather than verified receipts or total savings for all members. At 30 days, the separate matched group (n=60) averaged $389 at baseline and $394 at follow-up. The 90-day result is preliminary and based on a small group.
*4 Helpfulness: One session-10 response per member. 90 rated Nervana “very helpful” or “somewhat helpful”; another 6 reported a specific benefit in the same session. Together, that is 96/105 (91%). The remaining respondents reported “too early to tell” (8) or “not helpful” (1).